Potential for elimination of SAR‐CoV‐2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination
The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, fu...
Saved in:
Published in | Journal of medical virology Vol. 92; no. 11; pp. 2453 - 2457 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.11.2020
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 and humans. Elimination of SARS‐CoV‐2 through vaccination to avoid the potential long‐term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS‐CoV‐2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID‐19 and elucidates the importance of the development of more live vaccines for COVID‐19.
Highlights
Future vaccination against coronavirus disease 2019 (COVID‐19) may fall into long‐term costly guerrilla warfare between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and humans.
Elimination of SARS‐CoV‐2 through vaccination is highly desired and worth intensive consideration.
Multiple influenza viruses have been eliminated through natural pandemics or mass vaccination.
The coming 2 years are a golden time for the elimination of SARS‐CoV‐2 through mass vaccination.
Rapid establishment of global herd immunity through vaccination using a live vaccine could eliminate SARS‐CoV‐2. |
---|---|
AbstractList | The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 and humans. Elimination of SARS‐CoV‐2 through vaccination to avoid the potential long‐term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS‐CoV‐2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID‐19 and elucidates the importance of the development of more live vaccines for COVID‐19.
Future vaccination against coronavirus disease 2019 (COVID‐19) may fall into long‐term costly guerrilla warfare between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and humans.
Elimination of SARS‐CoV‐2 through vaccination is highly desired and worth intensive consideration.
Multiple influenza viruses have been eliminated through natural pandemics or mass vaccination.
The coming 2 years are a golden time for the elimination of SARS‐CoV‐2 through mass vaccination.
Rapid establishment of global herd immunity through vaccination using a live vaccine could eliminate SARS‐CoV‐2. The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID-19 may fall into long-term costly guerrilla warfare between SARS-CoV-2 and humans. Elimination of SARS-CoV-2 through vaccination to avoid the potential long-term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS-CoV-2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID-19 and elucidates the importance of the development of more live vaccines for COVID-19.The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID-19 may fall into long-term costly guerrilla warfare between SARS-CoV-2 and humans. Elimination of SARS-CoV-2 through vaccination to avoid the potential long-term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS-CoV-2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID-19 and elucidates the importance of the development of more live vaccines for COVID-19. The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 and humans. Elimination of SARS‐CoV‐2 through vaccination to avoid the potential long‐term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS‐CoV‐2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID‐19 and elucidates the importance of the development of more live vaccines for COVID‐19. Highlights Future vaccination against coronavirus disease 2019 (COVID‐19) may fall into long‐term costly guerrilla warfare between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and humans. Elimination of SARS‐CoV‐2 through vaccination is highly desired and worth intensive consideration. Multiple influenza viruses have been eliminated through natural pandemics or mass vaccination. The coming 2 years are a golden time for the elimination of SARS‐CoV‐2 through mass vaccination. Rapid establishment of global herd immunity through vaccination using a live vaccine could eliminate SARS‐CoV‐2. The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID-19 may fall into long-term costly guerrilla warfare between SARS-CoV-2 and humans. Elimination of SARS-CoV-2 through vaccination to avoid the potential long-term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS-CoV-2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID-19 and elucidates the importance of the development of more live vaccines for COVID-19. The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 and humans. Elimination of SARS‐CoV‐2 through vaccination to avoid the potential long‐term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS‐CoV‐2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID‐19 and elucidates the importance of the development of more live vaccines for COVID‐19. |
Author | Sun, Ying‐Xue Chen, Ji‐Wang Chen, Ji‐Ming |
AuthorAffiliation | 1 College of Veterinary Medicine Qingdao Agricultural University Qingdao China 3 Department of Medicine University of Illinois at Chicago Chicago Illinois 2 Qingdao Six‐Eight Nearby Sci‐Tech Company Qingdao China |
AuthorAffiliation_xml | – name: 1 College of Veterinary Medicine Qingdao Agricultural University Qingdao China – name: 2 Qingdao Six‐Eight Nearby Sci‐Tech Company Qingdao China – name: 3 Department of Medicine University of Illinois at Chicago Chicago Illinois |
Author_xml | – sequence: 1 givenname: Ji‐Ming orcidid: 0000-0002-0404-0830 surname: Chen fullname: Chen, Ji‐Ming email: jmchen678@qq.com organization: Qingdao Six‐Eight Nearby Sci‐Tech Company – sequence: 2 givenname: Ying‐Xue surname: Sun fullname: Sun, Ying‐Xue organization: Qingdao Six‐Eight Nearby Sci‐Tech Company – sequence: 3 givenname: Ji‐Wang surname: Chen fullname: Chen, Ji‐Wang organization: University of Illinois at Chicago |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32525587$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kktuFDEQhi0URCaBBRdAltjAohM_-7FBikY8FQTika3ltt0Zj9x2x-4eNKw4ApfgYpwEJzMThRFsbKnqq79-l-sIHPjgDQCPMTrBCJHTZb86ISUuyT0ww6gpiwZV-ADMEGZlUZaYH4KjlJYIoboh5AE4pIQTzutqBn59DKPxo5UOdiFC42xvvRxt8DB08PPZp98_fs7DRT4JHBcxTJcLuJJK7SCZoPVpsNFo2K736_vJjXZwJjOdm4z_LuHKximZdCuW4Snm7oP02vRWJZht9DKlu20egvuddMk82t7H4Ourl1_mb4rzD6_fzs_OC8VpRQrdMI0kq-paUsQb3nZU8pyiSvPrIGuZJjnMcadaTrCkhNGmamqtMdK0osfgxUZ3mNreaJUnk72JIdpexrUI0oq_M94uxGVYiYoiVFKUBZ5tBWK4mkwaRW-TMs5Jb8KUBGGYENRUZZ3Rp3voMkzR5-dlipVNzRmmmXpy19Gtld0PZuB0A6gYUoqmE8qON0PLBq0TGInrHRF5R8TNjuSK53sVO9F_sVv1b9aZ9f9B8e79xabiD5fc0NQ |
CitedBy_id | crossref_primary_10_4081_jphr_2022_2665 crossref_primary_10_1002_jmv_26453 crossref_primary_10_1177_22799036221107062 crossref_primary_10_1002_jmv_27661 crossref_primary_10_1002_jmv_26312 crossref_primary_10_1007_s11356_021_17055_8 crossref_primary_10_1002_jmv_27335 crossref_primary_10_1007_s00705_023_05815_5 |
Cites_doi | 10.1371/journal.pone.0011184 10.1016/j.vaccine.2016.07.033 10.1016/S0140-6736(20)30566-3 10.1128/mBio.00150-11 10.1007/s11427-018-9420-1 10.1128/JVI.00855-16 10.1038/d41573-020-00073-5 10.1186/s12985-019-1188-7 10.1371/journal.pone.0232652 10.1016/j.rvsc.2020.04.009 10.3201/eid2012.140733 10.1371/journal.ppat.1005215 10.1038/d41586-020-01221-y 10.24272/j.issn.2095-8137.2019.045 |
ContentType | Journal Article |
Copyright | 2020 Wiley Periodicals LLC 2020 Wiley Periodicals LLC. |
Copyright_xml | – notice: 2020 Wiley Periodicals LLC – notice: 2020 Wiley Periodicals LLC. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
DOI | 10.1002/jmv.26162 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
DocumentTitleAlternate | CHEN et al |
EISSN | 1096-9071 |
EndPage | 2457 |
ExternalDocumentID | PMC7300630 32525587 10_1002_jmv_26162 JMV26162 |
Genre | reviewArticle Journal Article Review |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WJL WNSPC WOHZO WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QL 7TK 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
ID | FETCH-LOGICAL-c5372-d94d0a4788a30595bf3a5c533cd5788a4b4d295b51fcb521a32439798dd10d373 |
IEDL.DBID | DR2 |
ISSN | 0146-6615 1096-9071 |
IngestDate | Thu Aug 21 14:34:10 EDT 2025 Fri Jul 11 08:03:23 EDT 2025 Sat Jul 26 02:17:21 EDT 2025 Wed Feb 19 02:29:08 EST 2025 Tue Jul 01 02:24:45 EDT 2025 Thu Apr 24 22:59:04 EDT 2025 Wed Jan 22 16:32:34 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | COVID-19 herd immunity influenza SARS-CoV-2 vaccine pandemic elimination vaccination |
Language | English |
License | 2020 Wiley Periodicals LLC. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5372-d94d0a4788a30595bf3a5c533cd5788a4b4d295b51fcb521a32439798dd10d373 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
ORCID | 0000-0002-0404-0830 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7300630 |
PMID | 32525587 |
PQID | 2446985413 |
PQPubID | 105515 |
PageCount | 5 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7300630 proquest_miscellaneous_2412209768 proquest_journals_2446985413 pubmed_primary_32525587 crossref_citationtrail_10_1002_jmv_26162 crossref_primary_10_1002_jmv_26162 wiley_primary_10_1002_jmv_26162_JMV26162 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2020 |
PublicationDateYYYYMMDD | 2020-11-01 |
PublicationDate_xml | – month: 11 year: 2020 text: November 2020 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: London – name: Hoboken |
PublicationTitle | Journal of medical virology |
PublicationTitleAlternate | J Med Virol |
PublicationYear | 2020 |
Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
References | 2011; 2 1963; 88 2019; 40 2016; 90 2020; 580 2020; 131 2020 2020; 395 2015; 11 2019; 16 2020; 15 2018; 61 2003 2010; 5 2020; 19 2016; 34 2014; 20 e_1_2_9_22_1 e_1_2_9_10_1 e_1_2_9_13_1 Liu S (e_1_2_9_11_1) 2020 e_1_2_9_12_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 Bloom BR (e_1_2_9_16_1) 2003 Zhou X (e_1_2_9_7_1) 2020 Gao Q (e_1_2_9_6_1) 2020 e_1_2_9_9_1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_19_1 e_1_2_9_18_1 Chen JW (e_1_2_9_21_1) 2020 Couch RB (e_1_2_9_20_1) 1963; 88 |
References_xml | – volume: 90 start-page: 9797 issue: 21 year: 2016 end-page: 9805 article-title: Characterization of clade 7.2 H5 avian influenza viruses that continue to circulate in chickens in China publication-title: J Virol – volume: 580 start-page: 576 issue: 7805 year: 2020 end-page: 577 article-title: The race for coronavirus vaccines: a graphical guide publication-title: Nature – volume: 131 start-page: 21 year: 2020 end-page: 23 article-title: COVID‐19 from veterinary medicine and one health perspectives: what animal coronaviruses have taught us publication-title: Res Vet Sci – volume: 16 start-page: 85 issue: 1 year: 2019 article-title: Diversity and distribution of type A influenza viruses: an updated panorama analysis based on protein sequences publication-title: Virol J – volume: 61 start-page: 1465 issue: 12 year: 2018 end-page: 1473 article-title: Vaccination of poultry successfully eliminated human infection with H7N9 virus in China publication-title: Sci China: Life Sci – year: 2003 – volume: 395 start-page: 1054 issue: 10229 year: 2020 end-page: 1062 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study publication-title: Lancet – start-page: 26 year: 2020 article-title: Follow‐up of asymptomatic patients with SARS‐CoV‐2 infection publication-title: Clin Microbiol Infect – start-page: 92 year: 2020 article-title: Potential of live pathogen vaccines for defeating the COVID‐19 pandemic: history and mechanism publication-title: J Med Virol – volume: 15 issue: 5 year: 2020 article-title: Herd immunity and a vaccination game: an experimental study publication-title: PLOS One – volume: 40 start-page: 305 issue: 4 year: 2019 end-page: 316 article-title: Effect of temperature on antioxidant defense and innate immunity in Brandt's voles publication-title: Zool Res – volume: 5 issue: 6 year: 2010 article-title: The re‐emergence of H1N1 influenza virus in 1977: a cautionary tale for estimating divergence times using biologically unrealistic sampling dates publication-title: PLOS One – volume: 19 start-page: 305 issue: 5 year: 2020 end-page: 306 article-title: The COVID‐19 vaccine development landscape publication-title: Nat Rev Drug Discov – volume: 11 issue: 10 year: 2015 article-title: Identification of the mechanisms causing reversion to virulence in an attenuated SARS‐CoV for the design of a genetically stable vaccine publication-title: PLOS Pathog – start-page: 67 year: 2020 article-title: Control of avian influenza in China: strategies and lessons publication-title: Transbound Emerg Dis – start-page: 368 year: 2020 article-title: Rapid development of an inactivated vaccine candidate for SARS‐CoV‐2 publication-title: Science – volume: 2 issue: 5 year: 2011 article-title: Why do influenza virus subtypes die out? A hypothesis publication-title: mBio – volume: 88 start-page: 394 issue: Suppl year: 1963 end-page: 403 article-title: Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract publication-title: Am Rev Respir Dis – volume: 34 start-page: 4558 issue: 38 year: 2016 end-page: 4564 article-title: Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits publication-title: Vaccine – volume: 20 start-page: 2152 issue: 12 year: 2014 end-page: 2154 article-title: Subclinical highly pathogenic avian influenza virus infection among vaccinated chickens, China publication-title: Emerg Infect Dis – ident: e_1_2_9_10_1 doi: 10.1371/journal.pone.0011184 – ident: e_1_2_9_19_1 doi: 10.1016/j.vaccine.2016.07.033 – ident: e_1_2_9_22_1 doi: 10.1016/S0140-6736(20)30566-3 – ident: e_1_2_9_8_1 doi: 10.1128/mBio.00150-11 – ident: e_1_2_9_14_1 doi: 10.1007/s11427-018-9420-1 – start-page: 92 year: 2020 ident: e_1_2_9_21_1 article-title: Potential of live pathogen vaccines for defeating the COVID‐19 pandemic: history and mechanism publication-title: J Med Virol – ident: e_1_2_9_12_1 doi: 10.1128/JVI.00855-16 – ident: e_1_2_9_17_1 – ident: e_1_2_9_2_1 doi: 10.1038/d41573-020-00073-5 – ident: e_1_2_9_9_1 doi: 10.1186/s12985-019-1188-7 – ident: e_1_2_9_15_1 doi: 10.1371/journal.pone.0232652 – ident: e_1_2_9_4_1 doi: 10.1016/j.rvsc.2020.04.009 – ident: e_1_2_9_13_1 doi: 10.3201/eid2012.140733 – ident: e_1_2_9_18_1 – volume-title: The Vaccine Book year: 2003 ident: e_1_2_9_16_1 – volume: 88 start-page: 394 year: 1963 ident: e_1_2_9_20_1 article-title: Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract publication-title: Am Rev Respir Dis – ident: e_1_2_9_5_1 doi: 10.1371/journal.ppat.1005215 – start-page: 368 year: 2020 ident: e_1_2_9_6_1 article-title: Rapid development of an inactivated vaccine candidate for SARS‐CoV‐2 publication-title: Science – start-page: 67 year: 2020 ident: e_1_2_9_11_1 article-title: Control of avian influenza in China: strategies and lessons publication-title: Transbound Emerg Dis – ident: e_1_2_9_3_1 doi: 10.1038/d41586-020-01221-y – start-page: 26 year: 2020 ident: e_1_2_9_7_1 article-title: Follow‐up of asymptomatic patients with SARS‐CoV‐2 infection publication-title: Clin Microbiol Infect – ident: e_1_2_9_23_1 doi: 10.24272/j.issn.2095-8137.2019.045 |
SSID | ssj0008922 |
Score | 2.3736928 |
SecondaryResourceType | review_article |
Snippet | The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed... The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2453 |
SubjectTerms | Avian flu Coronaviridae Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology elimination Herd immunity Humans Immunity Immunity, Herd Influenza International cooperation Mass Vaccination - statistics & numerical data Orthomyxoviridae pandemic Pandemics Pandemics - prevention & control Public health Respiratory diseases Review Reviews SARS‐CoV‐2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 vaccination vaccine Vaccines Viral diseases Virology Viruses Warfare |
Title | Potential for elimination of SAR‐CoV‐2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.26162 https://www.ncbi.nlm.nih.gov/pubmed/32525587 https://www.proquest.com/docview/2446985413 https://www.proquest.com/docview/2412209768 https://pubmed.ncbi.nlm.nih.gov/PMC7300630 |
Volume | 92 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPSAuUN6hBRnEgUu2iR3nIU5VRVVVWoQKrXpAivxadYFNqmZ3JXriJ_An-GP8EmacR7stSIhLFMWT2Elm7M-e8TcAr2QWWxmZOJQqxgmK0i4scBoRmlRwgeNb5PwOufG7dP8oOTiRJ2vwpt8L0_JDDAtuZBm-vyYDV7rZviQN_TxbjhD--_6XYrUIEB1eUkflRetBwJ4gxDFI9qxCEd8e7lwdi24AzJtxklfxqx-A9u7Cp77pbdzJl9Firkfm4hqr43--2wbc6YAp22k16R6sueo-3Bp3rvcH8PN9PafIIpRBnMuwAgqiod_K6gn7sHP46_uP3foYj5x1yX_YUhnTC6mGTSty6zvL9Lfr9_dxjSjjk6ZcKLacni8a1wwP8xSkWPsZLXvPpqZh2IwZYv-r1TyEo723H3f3wy7HQ2ikyHhoi8RGijj8FfY8hdQToSQWCWMlXUx0YjlelvHEaIQaCgEguSJza-PIikw8gvWqrtwTYMJqITI5SW2mEiWSPI2d5EZobhHYWRPA6_5vl6YjQKc8HF_LlrqZl_jZS__ZA3g5iJ61rB9_EtrqVabsDL8pES2lRS4RGgTwYihGkyU_jKpcvSCZmPMIcWAewONWw4ZaBJc4ycuzALIV3RsEiA58taSannpacMo8kIoIX9Or1t8bXh6Mj_3J038X3YTbnFYa_C7MLVifny_cM4Rjc_3c291vE_g2bg |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6VIgGXQvkNFDAIJC7ZJnacnwOHqqXa_myFSlv1FhzbKxa6SdXsLmpPPAIvwY1X4SV4EsbOT7ttkbj0wCWK4kns2GPPZ3v8DcArHvmKe9J3ufBxgiIy7SY4jXBlyChD--Zpe0KutxV2d4P1fb4_Az-bszAVP0S74GZ6hh2vTQc3C9KLp6yhn4eTDuL_kNYulRv6-CtO2Mq3ayvYuq8pXX23s9x165gCruQsoq5KAuUJwxkvUNMTnvWZ4JjEpOLmYZAFiuJj7vdlhqZNIOAwW1-xUr6nWMTwu9fguokgbpj6V7ZPyaripNqzwLHHRavHGx4jjy62RZ22fhcg7UXPzLOI2Zq81dvwq6msytPlS2c8yjry5ByP5P9Sm3dgrsbeZKnqLPMwo_O7cKNXexfcgx_vi5FxnkIZhPIE_8j4CRnNJUWffFja_v3t-3Kxh1dK6vhGZCKkbIRESQa58VzQimTH599vXDdRxsaFORFkMjgal7psP2ZZVjH3Q7OyPxzIkmAxhji9OZvNfdi9kkp6ALN5ketHQJjKGIt4P1SRCAQL4tDXnEqWUYXYVUkH3jTqlcqa492EGjlIK3ZqmmIzp7aZHXjZih5WxCaXCS00OprWY1uZIiAMk5gj-nHgRZuMo5LZahK5LsZGxqfUQ6gbO_CwUuk2F0Y5zmPjyIFoStlbAcN4Pp2SDz5Z5nMTXCFkHv6m1eW_Fzxd7-3Zm8f_LvocbnZ3epvp5trWxhO4Rc3Cij10ugCzo6Oxforoc5Q9s52ewMer7hd_AKfXkgo |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0qRarY8H4EChgEEptMEzvOY8Gi6jDqg6mqQqvuUsd2xACTGTUzg9oVn8BPsOJX-Aq-hGvn0U4LEpsu2ERRfBM79rXvsX19LsALHvmKe9J3ufBxgiIy7SY4jXBlyChD--Zpe0Kuvx2u7wWbB_xgAX40Z2Eqfoh2wc30DDtemw4-VvnKKWnox-Gsg_A_pLVH5ZY-_oLztfL1Rhcb9yWlvTfv19bdOqSAKzmLqKuSQHnCUMYLVPSEZzkTHJOYVNw8DLJAUXzM_VxmaNkE4g2z8xUr5XuKRQy_ewWuBqGXmDgR3d1Trqo4qbYscOhx0ejxhsbIoyttUeeN3wVEe9Ex8yxgthavdwN-NnVVObp86kwnWUeenKOR_E8q8yZcr5E3Wa26yi1Y0MVtWOrXvgV34PvOaGJcp1AGgTzBHzJeQkZvySgn71Z3f339tjbaxysldXQjMhNSNkKiJIPC-C1oRbLj8-83jpsoY6PCnAgyGxxNS122H7Mcq5j72KzrDweyJFiMIU5uzmZzF_YupZLuwWIxKvQDIExljEU8D1UkAsGCOPQ1p5JlVCFyVdKBV412pbJmeDeBRj6nFTc1TbGZU9vMDjxvRccVrcmfhJYbFU3rka1MEQ6GScwR-zjwrE3GMclsNIlCj6ZGxqfUQ6AbO3C_0ug2F0Y5zmLjyIFoTtdbAcN3Pp9SDD5Y3nMTWiFkHv6mVeW_Fzzd7O_bm4f_LvoUlna6vfTtxvbWI7hGzaqKPXG6DIuTo6l-jNBzkj2xXZ7A4WV3i99eDpC5 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Potential+for+elimination+of+SAR-CoV-2+through+vaccination+as+inspired+by+elimination+of+multiple+influenza+viruses+through+natural+pandemics+or+mass+vaccination&rft.jtitle=Journal+of+medical+virology&rft.au=Chen%2C+Ji-Ming&rft.au=Sun%2C+Ying-Xue&rft.au=Chen%2C+Ji-Wang&rft.date=2020-11-01&rft.eissn=1096-9071&rft.volume=92&rft.issue=11&rft.spage=2453&rft_id=info:doi/10.1002%2Fjmv.26162&rft_id=info%3Apmid%2F32525587&rft.externalDocID=32525587 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |